Loading
Life sciences · Journal article
Cureus · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
A 70-year-old man with extensive-stage small-cell lung cancer received palliative thoracic radiotherapy to a total dose of 18 Gy in six fractions for central airway stenosis.Five months later, second-line amrubicin was initiated.After two courses of treatment, he was admitted with fever and cough and was initially treated for suspected bacterial pneumonia.Despite cefepime treatment, computed tomography revealed worsening pulmonary opacities corresponding to the previously irradiated field.Bronchoscopy showed no visible endobronchial tumor, cytology revealed no malignant cells, and microbiological studies were negative.Amrubicin-induced radiation recall pneumonitis (RRP) was clinically diagnosed.Amrubicin was discontinued, and oral prednisolone was initiated at 30 mg/day, resulting in rapid clinical and radiographic improvement.Prednisolone was subsequently tapered to 10 mg/day without radiographic worsening at that dose.This case highlights that RRP should be considered after amrubicin therapy, even when the previous thoracic radiation dose was relatively low.